369 related articles for article (PubMed ID: 18829726)
1. Pre-clinical experience with daptomycin.
Hawkey PM
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii7-14. PubMed ID: 18829726
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
Rybak MJ
Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
[TBL] [Abstract][Full Text] [Related]
3. Daptomycin: rationale and role in the management of skin and soft tissue infections.
Seaton RA
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
[TBL] [Abstract][Full Text] [Related]
4. The use of daptomycin for Staphylococcus aureus infections in critical care medicine.
Alder J
Crit Care Clin; 2008 Apr; 24(2):349-63, ix-x. PubMed ID: 18361950
[TBL] [Abstract][Full Text] [Related]
5. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections].
Mathiesen L; Midtvedt T; Solberg CO
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2383-4. PubMed ID: 16998552
[TBL] [Abstract][Full Text] [Related]
6. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
Carpenter CF; Chambers HF
Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
[TBL] [Abstract][Full Text] [Related]
7. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria.
Johnson A
Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638
[TBL] [Abstract][Full Text] [Related]
8. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
9. Daptomycin.
Enoch DA; Bygott JM; Daly ML; Karas JA
J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
Steenbergen JN; Alder J; Thorne GM; Tally FP
J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
[TBL] [Abstract][Full Text] [Related]
11. Daptomycin: a review 4 years after first approval.
Sauermann R; Rothenburger M; Graninger W; Joukhadar C
Pharmacology; 2008; 81(2):79-91. PubMed ID: 17940348
[TBL] [Abstract][Full Text] [Related]
12. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
[TBL] [Abstract][Full Text] [Related]
13. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
14. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
Kanafani ZA; Corey GR
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833
[TBL] [Abstract][Full Text] [Related]
15. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD.
Eisenstein BI; Oleson FB; Baltz RH
Clin Infect Dis; 2010 Jan; 50 Suppl 1():S10-5. PubMed ID: 20067387
[TBL] [Abstract][Full Text] [Related]
16. Treatment of staphylococcal infections with cyclic lipopeptides.
Eisenstein BI
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():10-6. PubMed ID: 18226085
[TBL] [Abstract][Full Text] [Related]
17. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
DeRyke CA; Sutherland C; Zhang B; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
[TBL] [Abstract][Full Text] [Related]
18. [Daptomycin: revitalizing a former drug due to the need of new active agents against grampositive multiresistant bacterias].
Hernández Martí V; Romá Sánchez E; Salavert Lletí M; Bosó Ribelles V; Poveda Andrés JL
Rev Esp Quimioter; 2007 Sep; 20(3):261-76. PubMed ID: 18080024
[TBL] [Abstract][Full Text] [Related]
19. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections.
Kern WV
Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.
Benvenuto M; Benziger DP; Yankelev S; Vigliani G
Antimicrob Agents Chemother; 2006 Oct; 50(10):3245-9. PubMed ID: 17005801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
